Obesity Treatment
-
Morning Squawk: Novo Nordisk’s Obesity Pill, Alphabet’s Data Center Deal, Fading EV Hype, and More
Novo Nordisk’s FDA approval for the first oral obesity pill marks a significant shift, democratizing weight management beyond injections. This move, priced affordably, boosts Novo Nordisk shares and intensifies competition with Eli Lilly. The article also covers Dominion Energy’s offshore wind project halt, Skydance Media’s bid for Warner Bros. Discovery, Alphabet’s data center acquisition, and the EV sector’s recalibration amidst slower-than-expected demand. Instacart is ending controversial AI pricing tests due to consumer concerns, and US gasoline prices have hit four-year lows.
